Found: 4

Select item for more details and to access through your institution.

  • Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice.

    Published in:
    Clinical & Translational Oncology, 2020, v. 22, n. 10, p. 1778, doi. 10.1007/s12094-020-02315-9
    By:
    • Pérez-Ruiz, E.;
    • Jiménez-Castro, J.;
    • Berciano-Guerrero, M.-A.;
    • Valdivia, J.;
    • Estalella-Mendoza, S.;
    • Toscano, F.;
    • Rodriguez de la Borbolla Artacho, M.;
    • Garrido-Siles, M.;
    • Martínez-Bautista, M. J.;
    • Villatoro Roldan, R.;
    • Rivas-Ruiz, F.;
    • Nogales-Fernández, E.;
    • Morales, C.;
    • Pérez-Valderrama, B.;
    • De la Cruz-Merino, L.;
    • Rueda, A.
    Publication type:
    Article

  • New horizons in breast cancer: the promise of immunotherapy.

    Published in:
    Clinical & Translational Oncology, 2019, v. 21, n. 2, p. 117, doi. 10.1007/s12094-018-1907-3
    By:
    • de la Cruz-Merino, L.;
    • Palazón-Carrión, N.;
    • Henao-Carrasco, F.;
    • Nogales-Fernández, E.;
    • Álamo-de la Gala, M.;
    • Vallejo-Benítez, A.;
    • Chiesa, M.;
    • Sánchez-Margalet, V.;
    • GEICAM (Spanish Breast Cancer Research Group) and GÉTICA (Spanish Group for Cancer Immuno-Biotherapy)
    Publication type:
    Article

  • LENALIDOMIDE PLUS R‐GDP (R2‐GDP) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. PRELIMINARY RESULTS OF THE R2‐GDP‐GOTEL TRIAL.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 258, doi. 10.1002/hon.67_2630
    By:
    • Cruz‐Merino, L.;
    • Martín García‐Sancho, A.;
    • Nogales Fernández, E.;
    • Carnicero González, F.;
    • Ríos Herranz, E.;
    • Cruz Vicente, F.;
    • Rodríguez García, G.;
    • Nicolás García, C.;
    • Martínez Benaclocha, N.;
    • Gumà Padrò, J.;
    • Gómez Codina, J.;
    • Salar Silvestre, A.;
    • Rodríguez Abreu, D.;
    • Quero Blanco, C.;
    • Labrador Gómez, J.;
    • Guirado Risueño, M.;
    • Provencio Pulla, M.;
    • Rueda Domínguez, A.
    Publication type:
    Article

  • LENALIDOMIDE PLUS R‐GDP (R2‐GDP) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. PRELIMINARY RESULTS OF THE R2‐GDP‐GOTEL TRIAL.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 258, doi. 10.1002/hon.67_2630
    By:
    • Cruz‐Merino, L.;
    • Martín García‐Sancho, A.;
    • Nogales Fernández, E.;
    • Carnicero González, F.;
    • Ríos Herranz, E.;
    • Cruz Vicente, F.;
    • Rodríguez García, G.;
    • Nicolás García, C.;
    • Martínez Benaclocha, N.;
    • Gumà Padrò, J.;
    • Gómez Codina, J.;
    • Salar Silvestre, A.;
    • Rodríguez Abreu, D.;
    • Quero Blanco, C.;
    • Labrador Gómez, J.;
    • Guirado Risueño, M.;
    • Provencio Pulla, M.;
    • Rueda Domínguez, A.
    Publication type:
    Article